Relationship between rs3918242 Polymorphism of Matrix Methaloproteinase-9 Gene and Preeclampsia in Pregnant Women

authors:

avatar Mehdi Sahmani 1 , avatar Nilofar Ahmadi 1 , avatar Somayeh Asadian 2 , avatar Talaat Dabaghi Ghaleh 2 , avatar Amir Javadi ORCID 3 , *

Cellular and Molecular Research Center, Qazvin University of Medical Sciences, Qazvin, Iran.
Department of Obstetrics and Gynecology, Kosar Hospital, School of Medicine, Qazvin University of Medical Science, Qazvin, Iran.
Department of Social Science, School of Medicine, Qazvin University of Medical Science, Qazvin, Iran.
Journal of Inflammatory Diseases: Vol.24, issue 5; 434-443
article type: issue_documents_importer

How To Cite Sahmani M, Ahmadi N, Asadian S, Dabaghi Ghaleh T, Javadi A. Relationship between rs3918242 Polymorphism of Matrix Methaloproteinase-9 Gene and Preeclampsia in Pregnant Women. J Inflamm Dis. 2020;24(5):e156243. 

Abstract

Background: Preeclampsia is a complex disorder of pregnancy with an unknown etiology. Numerous studies have shown the possible role of gene polymorphisms, especially metalloproteinases, in development of this disease, but there are no definitive results. Objective: This study aims to investigate the possible association between rs3918242 (−1562C>T) polymorphism in Matrix Metalloproteinase 9 (MMP9) gene with the risk of preeclampsia in pregnant women. Methods: In this cross-sectional study, participants were 90 pregnant women with preeclampsia and 199 healthy pregnant women (controls). The genotypes of rs3918242 polymorphism were investigated using Polymerase Chain Reaction technique and Limited Fragment Length Polymorphism method. Logistic regression analysis was used to investigate the relationship between rs3918242 polymorphism and preeclampsia.  Findings: The frequency of CC, CT, TT genotypes of rs3918242 polymorphism was reported 47.8%, 47.8% and 4.2% in patients and 84.8, 13.1 and 2% in controls, respectively, and the difference between groups was significant (P<0.001). The frequency of TT genotype in patients was significantly higher than in controls (P<0.001). Moreover, the frequency of T allele in patients was 52.2%, while in controls it was 15.2% and the difference between the two groups was significant (P<0.001). Conclusion: The rs3918242 polymorphism of MMP9 gene plays an important role in the incidence of preeclampsia in pregnant women.

References

  • 1.

    Mayrink J, Costa ML, Cecatti JG. Preeclampsia in 2018: Revisiting concepts, physiopathology, and prediction. Sci World J. 2018; 2018:6268276. [DOI:10.1155/2018/6268276] [PMID] [PMCID].

  • 2.

    Ahmed NA, Hamdan HZ, Kamis AH, Adam I. The association of the prothrombin G20210A single-nucleotide polymorphism and the risk of preeclampsia: Systematic review and metaanalysis. Eur J Obstet Gynecol Reprod Biol. 2020; 253:162-9. [DOI:10.1016/j.ejogrb.2020.08.005] [PMID].

  • 3.

    Hill LD, York TP, Kusanovic JP, Gomez R, Eaves LJ, Romero R, et al. Epistasis between COMT and MTHFR in maternalfetal dyads increases risk for preeclampsia. PLoS One. 2011; 6(1):e16681. [DOI:10.1371/journal.pone.0016681] [PMID] [PMCID].

  • 4.

    Sakowicz A, Lisowska M, Biesiada L, Rybak-Krzyszkowska M, Gach A, Sakowicz B, et al. Association of maternal and fetal single-nucleotide polymorphisms in metalloproteinase (MMP1, MMP2, MMP3, and MMP9) genes with preeclampsia. Dis Markers. 2018; 2018:1371425. [DOI:10.1155/2018/1371425] [PMID] [PMCID].

  • 5.

    Palei ACT, Sandrim VC, Amaral LM, Machado JSR, Cavalli RC, Lacchini R, et al. Matrix metalloproteinase-9 polymorphisms affect plasma MMP-9 levels and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy. Pharmacogenomics J. 2012; 12(6):489-98. [DOI:10.1038/tpj.2011.31] [PMID].

  • 6.

    Valenzuela FJ, Prez-Seplveda A, Torres MJ, Correa P, Repetto GM, Illanes SE. Pathogenesis of Preeclampsia: The Genetic component. J Pregnancy. 2012; 2012:632732. [DOI:10.1155/2012/632732] [PMID] [PMCID].

  • 7.

    Aas PA, Otterlei M, Falnes P, Vgb CB, Skorpen F, Akbari M, et al. Human and bacterial oxidative demethylases repair alkylation damage in both RNA and DNA. Nature. 2003; 421(6925):859-63. [DOI:10.1038/nature01363] [PMID].

  • 8.

    Bartek J, Lukas J. DNA repair: Damage alert. Nature. 2003; 421(6922):486-8. [DOI:10.1038/421486a] [PMID].

  • 9.

    Farina AR, Mackay AR. Gelatinase B/MMP-9 in tumour pathogenesis and progression. Cancers. 2014; 6(1):240-96. [DOI:10.3390/cancers6010240] [PMID] [PMCID].

  • 10.

    Awakura Y, Ito N, Nakamura E, Takahashi T, Kotani H, Mikami Y, et al. Matrix metalloproteinase-9 polymorphisms and renal cell carcinoma in a Japanese population. Cancer Lett. 2006; 241(1):59-63. [DOI:10.1016/j.canlet.2005.10.005] [PMID].

  • 11.

    Gai X, Lan X, Luo Z, Wang F, Liang Y, Zhang H, et al. Association of MMP-9 gene polymorphisms with atrial fibrillation in hypertensive heart disease patients. Clin Chim Acta. 2009; 408(12):105-9. [DOI:10.1016/j.cca.2009.07.020] [PMID].

  • 12.

    Wang L, Zhang D, Yu Y, Guan H, Qiao C, Shang T. RNA interference-mediated silencing of Laminin Receptor 1 (LR1) suppresses migration and invasion and down-regulates Matrix Metalloproteinase (MMP)-2 and MMP-9 in trophoblast cells: Implication in the pathogenesis of preeclampsia. J Mol Histol. 2013; 44(6):661-8. [DOI:10.1007/s10735-013-9515-6] [PMID].

  • 13.

    Rasstrigina IM, Milovanov AP, Fokina TV, Kadyrov M. The intensity of expression of matrix metalloproteinases type 2 and type 9 by invasive trophoblast cells in uncomplicated pregnancy and preeclampsia. Arkh Patol. 2014; 76(3):24-9. [In Russian] [PMID].

  • 14.

    Lockwood CJ, Basar M, Kayisli UA, Guzeloglu-Kayisli O, Murk W, Wang J, et al. Interferon- protects first-trimester decidual cells against aberrant matrix metalloproteinases 1, 3, and 9 expression in preeclampsia. Am J Pathol. 2014; 184(9):2549-59. [DOI:10.1016/j.ajpath.2014.05.025] [PMID] [PMCID].

  • 15.

    Mckirdy A, Marks L. PP060. Matrix metalloproteinases-2 and -9 and their inhibitors: A role in the development of preeclampsia? Pregnancy Hypertens Int J Womens Cardiovasc Health. 2012; 2(3):274-5. [DOI:10.1016/j.preghy.2012.04.171] [PMID].

  • 16.

    Feng H, Wang L, Zhang M, Zhang Z, Guo W, Wang X. Ratio of matrix metalloproteinase-2 to -9 is a more accurate predictive biomarker in women with suspected pre-eclampsia. Biosci Rep. 2017; 37(2):BSR20160508. [DOI:10.1042/BSR20160508] [PMID] [PMCID].

  • 17.

    Rahimi Z, Kazemian L, Malek-Khosravi Sh, Najafi F, Rahimi Z. Matrix metalloproteinase-7 A-181G and its interaction with matrix metalloproteinase-9 C-1562T polymorphism in preeclamptic patients: Association with malondialdehyde level and severe preeclampsia. Arch Gynecol Obstet. 2015; 291(1):4551. [DOI:10.1007/s00404-014-3376-4] [PMID].

  • 18.

    Verma S, Kesh K, Gupta A, Swarnakar S. An overview of matrix metalloproteinase 9 polymorphism and gastric cancer risk. Asian Pac J Cancer Prev. 2015; 16(17):7393-400. [DOI:10.7314/ APJCP.2015.16.17.7393] [PMID].

  • 19.

    Zhang Z, Wu X, Cai T, Gao W, Zhou X, Zhao J, et al. Matrix metalloproteinase 9 gene promoter (rs 3918242) mutation reduces the risk of diabetic microvascular complications. Int J Environ Res Public Health. 2015; 12(7):8023-33. [DOI:10.3390/ ijerph120708023] [PMID] [PMCID].

  • 20.

    Cotignola J, Reva B, Mitra N, Ishill N, Chuai Sh, Patel A, et al. Matrix Metalloproteinase-9 (MMP-9) polymorphisms in patients with cutaneous malignant melanoma. BMC Med Genet. 2007; 8:10. [DOI:10.1186/1471-2350-8-10] [PMID] [PMCID].

  • 21.

    Kang L, Chen CH, Yu CH, Chang CH, Chang FM. An association study of interleukin-4 gene and preeclampsia in Taiwan. Taiwan J Obstet Gynecol. 2014; 53(2):215-9. [DOI:10.1016/j. tjog.2014.04.017] [PMID].

  • 22.

    Sun C, Zhang Q, Hu B, Zhang K. Investigation of the association between matrix metalloproteinase-9 genetic polymorphisms and development of pre-eclampsia in Chinese pregnant women. Genet Mol Res. 2016; 15(3):gmr.15038355. [DOI:10.4238/gmr.15038355].

  • 23.

    Luizon MR, Palei ACT, Sandrim VC. Polymorphisms and haplotypes in candidate genes related to angiogenesis and endothelial dysfunction in preeclampsia. J Pregnancy. 2012; 2012:914704. [DOI:10.1155/2012/914704] [PMID] [PMCID].

  • 24.

    Coolman M, de Maat M, Van Heerde WL, Felida L, Schoormans S, Steegers EAP, et al. Matrix metalloproteinase-9 gene -1562C/T polymorphism mitigates preeclampsia. Placenta. 2007; 28(7):709-13. [DOI:10.1016/j.placenta.2006.06.017] [PMID].

  • 25.

    Leonardo DP, Albuquerque DM, Lanaro C, Baptista LC, Cecatti JG, Surita FG, et al. Association of nitric oxide synthase and matrix metalloprotease single nucleotide polymorphisms with preeclampsia and its complications. PLoS One. 2015; 10(8):e0136693. [DOI:10.1371/journal.pone.0136693] [PMID] [PMCID].

  • 26.

    Meng H, Qi M, Liu Y, Xu L, Li Q. Research on correlation between MMP-9 and early-onset preeclampsia. Int J Clin Exp Med. 2016; 9(9):17442-8. http://www.ijcem.com/files/ ijcem0034617.pdf.

  • 27.

    Laskowska M. Altered maternal serum Matrix Metalloproteinases MMP-2, MMP-3, MMP-9, and MMP-13 in severe early- and late-onset preeclampsia. Biomed Res Int. 2017; 2017:6432426. [DOI:10.1155/2017/6432426] [PMID] [PMCID]##.